Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924686 | 0.84 | — | — | |
| SCHEMBL21101837 | 0.80 | DPP4 (0.33) | DPP4 | |
| SCHEMBL420729 | 0.71 | DPP4 (0.37) | DPP4RAF1BRAF | |
| SCHEMBL2084465 | 0.71 | DPP4 (0.41) | DPP4RAF1BRAF | |
| SCHEMBL3830401 | 0.71 | DPP4 (0.41) | DPP4RAF1BRAF | |
| SCHEMBL8407070 | 0.70 | ADH1B (0.38) | — | |
| SCHEMBL15461395 | 0.69 | DPP4 (0.40) | DPP4RAF1BRAF | |
| SCHEMBL24736835 | 0.68 | DPP4 (0.42) | DPP4RAF1BRAF | |
| SCHEMBL19003153 | 0.67 | — | — | |
| SCHEMBL24004510 | 0.67 | DPP4 (0.35) | DPP4RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, PDXK, GCKR | DPP4 188/4885RAF1 192/4885BRAF 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.